Premium
Efficacy and acceptability of a mifepristone–misoprostol combined regimen for early induced abortion among women in Mexico City
Author(s) -
Peña Melanie,
Dzuba Ilana G.,
Smith Patricio Sanhueza,
Mendoza Luis Jorge Arellano,
Bousiéguez Manuel,
Martínez María Laura García,
Polanco Ranulfo Ríos,
Villalón Antonio Eduardo Flores,
Winikoff Beverly
Publication year - 2014
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2014.04.012
Subject(s) - misoprostol , mifepristone , medicine , medical abortion , abortion , obstetrics , regimen , gestation , gynecology , pregnancy , surgery , genetics , biology
Objective To evaluate the experience of women receiving mifepristone–misoprostol for early induced abortion in public sector facilities in the Federal District of Mexico City. Methods An open‐label prospective study was conducted with 1000 pregnant women who sought induced abortion with a pregnancy of up to 63 days of gestation, as measured from the date of their last menstrual period. The study was conducted in three public sector healthcare facilities: two secondary level hospitals and one primary care clinic. Women ingested 200 mg mifepristone on day 1, followed by 800 μg buccal misoprostol 24 hours later, and they returned for follow‐up on day 8. The primary outcome was complete abortion without recourse to surgical intervention. Results A total of 971 women received mifepristone–misoprostol and were included in the analysis for efficacy of treatment. The overall efficacy of the combined medical abortion regimen studied was 97.3% (n = 945); the success rate did not vary significantly by gestational age (95.9%–100%; P = 0.449). Most women (n = 922, 95.0%) had a successful induced abortion with only one dose of misoprostol. Conclusion The combined mifepristone and buccal misoprostol regimen was found to be highly effective and acceptable among Mexican women. www.ClinicalTrials.gov : NCT00386282.